Literature DB >> 26359263

Prognostic Value of Dual-Time-Point 18F-FDG PET for Idiopathic Pulmonary Fibrosis.

Yukihiro Umeda1, Yoshiki Demura2, Miwa Morikawa3, Masaki Anzai3, Maiko Kadowaki3, Shingo Ameshima3, Tatsuro Tsuchida4, Tetsuya Tsujikawa5, Yasushi Kiyono5, Hidehiko Okazawa5, Takeshi Ishizaki6, Tamotsu Ishizuka3.   

Abstract

UNLABELLED: The aim of this prospective study was to clarify whether dual-time-point (18)F-FDG PET imaging results are useful to predict long-term survival of idiopathic pulmonary fibrosis (IPF) patients.
METHODS: Fifty IPF patients underwent (18)F-FDG PET examinations at 2 time points: 60 min (early imaging) and 180 min (delayed imaging) after (18)F-FDG injection. The standardized uptake value (SUV) at each point and retention index value (RI-SUV) calculated from those were evaluated, and then the results were compared with overall and progression-free survival.
RESULTS: A multivariate Cox proportional hazards model showed higher RI-SUV and higher extent of fibrosis score as independent predictors of shorter progression-free survival. The median progression-free survival for patients with negative RI-SUV was better than that for those with positive RI-SUV (27.9 vs. 13.3 mo, P = 0.0002). On the other hand, multivariate Cox analysis showed higher RI-SUV and lower forced vital capacity to be independent predictors of shorter overall survival. The 5-y survival rate for patients with negative RI-SUV was better than that for those with positive RI-SUV (76.8% vs. 14.3%, P = 0.00001). In addition, a univariate Cox model showed that positive RI-SUV as a binary variable was a significant indicator of mortality (hazard ratio, 7.31; 95% confidence interval, 2.64-20.3; P = 0.0001).
CONCLUSION: Our results demonstrate that positive RI-SUV is strongly predictive of earlier deterioration of pulmonary function and higher mortality in patients with IPF.
© 2015 by the Society of Nuclear Medicine and Molecular Imaging, Inc.

Entities:  

Keywords:  fluorodeoxyglucose 18F; idiopathic pulmonary fibrosis; positron emission tomography; survival analysis

Mesh:

Substances:

Year:  2015        PMID: 26359263     DOI: 10.2967/jnumed.115.163360

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  16 in total

Review 1.  Imaging Pulmonary Inflammation.

Authors:  Philip M Scherer; Delphine L Chen
Journal:  J Nucl Med       Date:  2016-09-01       Impact factor: 10.057

2.  Glucose Transporter 1-Dependent Glycolysis Is Increased during Aging-Related Lung Fibrosis, and Phloretin Inhibits Lung Fibrosis.

Authors:  Soo Jung Cho; Jong-Seok Moon; Chang-Min Lee; Augustine M K Choi; Heather W Stout-Delgado
Journal:  Am J Respir Cell Mol Biol       Date:  2017-04       Impact factor: 6.914

3.  Type I collagen-targeted PET probe for pulmonary fibrosis detection and staging in preclinical models.

Authors:  Pauline Désogère; Luis F Tapias; Lida P Hariri; Nicholas J Rotile; Tyson A Rietz; Clemens K Probst; Francesco Blasi; Helen Day; Mari Mino-Kenudson; Paul Weinreb; Shelia M Violette; Bryan C Fuchs; Andrew M Tager; Michael Lanuti; Peter Caravan
Journal:  Sci Transl Med       Date:  2017-04-05       Impact factor: 17.956

4.  Impact of FDG-PET on the Detection of Patients with Lung Cancer at High Risk for ILD.

Authors:  Paul Flechsig; Olena Hural; Michael Kreuter; Martin Eichhorn; Gudula HEUßEL; Christos Sachpekidis; Hans-Ulrich Kauczor; Uwe Haberkorn; Claus Peter Heussel; Monika Eichinger
Journal:  In Vivo       Date:  2018 Nov-Dec       Impact factor: 2.155

Review 5.  Quantification of Lung PET Images: Challenges and Opportunities.

Authors:  Delphine L Chen; Joseph Cheriyan; Edwin R Chilvers; Gourab Choudhury; Christopher Coello; Martin Connell; Marie Fisk; Ashley M Groves; Roger N Gunn; Beverley F Holman; Brian F Hutton; Sarah Lee; William MacNee; Divya Mohan; David Parr; Deepak Subramanian; Ruth Tal-Singer; Kris Thielemans; Edwin J R van Beek; Laurence Vass; Jeremy W Wellen; Ian Wilkinson; Frederick J Wilson
Journal:  J Nucl Med       Date:  2017-01-12       Impact factor: 10.057

Review 6.  Pulmonary Functional Imaging: Part 2-State-of-the-Art Clinical Applications and Opportunities for Improved Patient Care.

Authors:  Warren B Gefter; Kyung Soo Lee; Mark L Schiebler; Grace Parraga; Joon Beom Seo; Yoshiharu Ohno; Hiroto Hatabu
Journal:  Radiology       Date:  2021-04-13       Impact factor: 29.146

7.  Consensus Recommendations on the Use of 18F-FDG PET/CT in Lung Disease.

Authors:  Delphine L Chen; Safia Ballout; Laigao Chen; Joseph Cheriyan; Gourab Choudhury; Ana M Denis-Bacelar; Elise Emond; Kjell Erlandsson; Marie Fisk; Francesco Fraioli; Ashley M Groves; Roger N Gunn; Jun Hatazawa; Beverley F Holman; Brian F Hutton; Hidehiro Iida; Sarah Lee; William MacNee; Keiko Matsunaga; Divya Mohan; David Parr; Alaleh Rashidnasab; Gaia Rizzo; Deepak Subramanian; Ruth Tal-Singer; Kris Thielemans; Nicola Tregay; Edwin J R van Beek; Laurence Vass; Marcos F Vidal Melo; Jeremy W Wellen; Ian Wilkinson; Frederick J Wilson; Tilo Winkler
Journal:  J Nucl Med       Date:  2020-09-18       Impact factor: 11.082

8.  [18F]FDG PET/CT predicts progression-free survival in patients with idiopathic pulmonary fibrosis.

Authors:  Aurélien Justet; Astrid Laurent-Bellue; Gabriel Thabut; Arnaud Dieudonné; Marie-Pierre Debray; Raphael Borie; Michel Aubier; Rachida Lebtahi; Bruno Crestani
Journal:  Respir Res       Date:  2017-04-27

9.  The lungs were on fire: a pilot study of 18F-FDG PET/CT in idiopathic-inflammatory-myopathy-related interstitial lung disease.

Authors:  Junyu Liang; Heng Cao; Yinuo Liu; Bingjue Ye; Yiduo Sun; Yini Ke; Ye He; Bei Xu; Jin Lin
Journal:  Arthritis Res Ther       Date:  2021-07-23       Impact factor: 5.156

10.  Pulmonary 18F-FDG uptake helps refine current risk stratification in idiopathic pulmonary fibrosis (IPF).

Authors:  Thida Win; Nicholas J Screaton; Joanna C Porter; Balaji Ganeshan; Toby M Maher; Francesco Fraioli; Raymondo Endozo; Robert I Shortman; Lynn Hurrell; Beverley F Holman; Kris Thielemans; Alaleh Rashidnasab; Brian F Hutton; Pauline T Lukey; Aiden Flynn; Peter J Ell; Ashley M Groves
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-01-16       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.